Diagnostics News and Research

RSS

Agfa HealthCare opens state-of-the-art, worldwide R&D facility for clinical imaging IT solutions development

Facility is a center of excellence for the design of innovative solutions that will bring further revolutionary developments for radiology, pathology and healthcare delivery as a whole to image-enable the Electronic Health Record (EHR)

17 May 2012

Project aims to find new diagnostic tools, drugs for triple negative breast cancer

Some types of breast cancer can be successfully treated with drugs such as tamoxifen, but treatment for a type of breast cancer more common in young and black women is still limited to radiation and general chemotherapy. Called triple negative breast cancer, this type of cancer is the focus of a 20-month, $8.6-million research project that aims to find new diagnostic tools and options for drugs.

17 May 2012

Dako, VARI partner to license, manufacture and distribute cancer diagnostics

Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody.

17 May 2012

NanoString commences second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay.

From NanoString Technologies 17 May 2012

Ultrasensitive biosensor may open up new opportunities for early detection of cancer

Researchers have created an ultrasensitive biosensor that could open up new opportunities for early detection of cancer and "personalized medicine" tailored to the specific biochemistry of individual patients.

16 May 2012

Vermillion first quarter total revenue increases to $312,000

Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the first quarter ended March 31, 2012.

From Quest Diagnostics 16 May 2012

Thermo Fisher signs asset purchase agreement with Nephromics for PlGF assay

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia.

From Thermo Fisher Scientific Inc. 16 May 2012

Lab21’s HCV drug resistance genotyping receives new patents in the U.S., Europe

Lab21 Limited, the Cambridge, UK-based specialist in personalised medicine has secured new patents in Europe and the USA relating to Hepatitis C (HCV) drug resistance as it continues to expand its intellectual property portfolio in infectious disease testing.

15 May 2012

Persistent Systems, TGen collaborate on Bio4D software program

Persistent Systems, the leader in outsourced software product development (OPD) services, and the Translational Genomics Research Institute (TGen) today announced that they are developing a high-quality biospecimen management system called Bio4D.

15 May 2012

Ono, Scil Proteins partner to discover and develop new Affilin therapeutics

Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, today announced that it has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd., for the joint discovery and development of new Affilin therapeutics to treat various diseases.

15 May 2012

CHDI, KineMed partner to investigate turnover rates of huntingtin protein

KineMed, Inc. and CHDI Foundation, Inc. announced today a collaboration to use KineMed's isotopic labeling and dynamic proteomics platform to investigate the turnover rates of huntingtin protein, a mutant form of which plays a central role in the pathogenesis of Huntington's disease (HD).

15 May 2012

OPKO receives U.S. patent allowance titled, ‘Flow Control in Microfluidic Systems’

OPKO Health, Inc. today announced the receipt of a patent allowance from the U.S. Patent and Trademark Office (USPTO) for the patent application titled "Flow Control in Microfluidic Systems".

15 May 2012

Positive data from Piramal Healthcare’s BST-CarGel Phase III cartilage repair trial

Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited, today announced that positive data from their pivotal (Phase III) clinical trial is being presented in 3 podium presentations as well as during an Industry Symposium at the 10th World Congress of the International Cartilage Repair Society (ICRS), May 12 to 15, in Montreal, Quebec, Canada.

14 May 2012

Trovagene receives European patent titled, ‘Methods for Detection of Nucleic Acid Sequences in Urine’

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."

11 May 2012

A Better Method for Diagnosing Kidney Disease

Assessing glomerular filtration rate (GFR) using kidney filtration markers in blood is the standard means for determining kidney function, diagnosing kidney disease and measuring its progression. A higher filtration rate indicates healthy kidney function, while a lower rate points to various stages of kidney disease. A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that the new CKD-EPI equation for calculating GFR is a better predictor of risk for kidney disease and death compared to the most widely used method. The findings suggest that switching to the CKD-EPI equation for calculating GFR could focus efforts more efficiently, and improve assessment of patient future risk and treatment of kidney disease. The study is published in the May 9 edition of JAMA.

10 May 2012

ACOEM honors JNJ with 2012 Corporate Health Achievement Award

Johnson & Johnson (JNJ) the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services for the consumer and pharmaceutical and medical devices and diagnostics markets, has been awarded the 2012 Corporate Health Achievement Award (CHAA) by the American College of Occupational and Environmental Medicine.

10 May 2012

Scientists develop new method to directly identify miRNA targets in cells

Human cells are thought to produce thousands of different microRNAs (miRNAs)-small pieces of genetic material that help determine which genes are turned on or off at a given time. miRNAs are an important part of normal cellular function, but they can also contribute to human disease-some are elevated in certain tumors, for example, where they promote cell survival.

10 May 2012

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.

10 May 2012

ArcDia completes € 2.7 million funding round

ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.

9 May 2012

IBN develops biochip for investigating the effect of drugs on cancer stem cells

Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs). Published recently in Nano Today, this new technology could boost the development of more effective cancer drugs.

9 May 2012